We came across a bearish thesis on uniQure N.V. on augur’s substack. In this article, we will summarize the bulls’ thesis on QURE. uniQure N.V.’s share was trading at $27.51 as of November 28th. QURE’s forward P/E was 27.93 according to Yahoo Finance.
goodluz/Shutterstock.com
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. QURE’s AMT-130 gene therapy faces significant scientific and strategic challenges in...
